Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...131132133134135136137138139140141...170171»
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Review, Journal:  Dermatosurgery in the age of novel oral anticoagulants/direct oral anticoagulants (Pubmed Central) -  Nov 22, 2019   
    While the guidelines are increasingly implemented in daily practice, there is still uncertainty concerning the use of the novel direct oral anticoagulants (NOAC = DOAC). In this review, we analyze current developments and formulate concise recommendations for continuation during skin surgery under consideration of individual risk.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Massive Spontaneous Haemothorax after Rivaroxaban Therapy for Acute Pulmonary Embolism. (Pubmed Central) -  Nov 22, 2019   
    It is important to recognise such danger signs warranting closer attention, especially since the increased use of direct oral anticoagulants has facilitated ambulatory care and this complication may manifest in the outpatient setting. Spontaneous haemothorax may occur in the first 2 weeks after a patient starts anticoagulation.Severe pleuritic pain in a patient with pulmonary embolism may indicate subclinical infarction near the visceral pleura with an increased risk of pleural effusion and the subsequent development of a spontaneous haemothorax.Patients with severe pain and pleural effusion should be monitored closely, especially if they are outpatients, even though initial radiological findings are not significant.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic Mfg.
    Journal:  Asymptomatic Cerebral Infarction During Catheter Ablation for Atrial Fibrillation: Comparing Uninterrupted Rivaroxaban and Warfarin (ASCERTAIN). (Pubmed Central) -  Nov 21, 2019   
    Spontaneous haemothorax may occur in the first 2 weeks after a patient starts anticoagulation.Severe pleuritic pain in a patient with pulmonary embolism may indicate subclinical infarction near the visceral pleura with an increased risk of pleural effusion and the subsequent development of a spontaneous haemothorax.Patients with severe pain and pleural effusion should be monitored closely, especially if they are outpatients, even though initial radiological findings are not significant. No notable differences were found between the incidence of CA-induced ACI in the rivaroxaban group and that in the warfarin group in this randomized study.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
    Journal:  Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. (Pubmed Central) -  Nov 21, 2019   
    P3
    The combination of rivaroxaban 2.5 mg twice daily plus aspirin or rivaroxaban 5 mg twice daily alone compared with aspirin alone did not reduce graft failure in patients with recent CABG surgery, but the combination of rivaroxaban 2.5 mg twice daily plus aspirin was associated with similar reductions in MACE, as observed in the larger COMPASS trial. (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS [COMPASS]; NCT01776424).
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg., IONIS-FXIRx / Bayer
    Journal:  Antithrombotic Agents. (Pubmed Central) -  Nov 21, 2019   
    The aims of this article are to review the results of recent trials aimed at enhancing the benefit-risk profile of antithrombotic therapy and explain how these findings are changing our approach to the management of arterial and venous thrombosis. Focusing on these 2 aspects of thrombosis management, this article discusses 4 advances: (1) the observation that in some indications, lowering the dose of some direct oral anticoagulants reduces the risk of bleeding without compromising efficacy, (2) the recognition that aspirin is not only effective for secondary prevention of atherothrombosis but also for prevention of venous thromboembolism, (3) the finding that dual pathway inhibition with the combination of low-dose rivaroxaban to attenuate thrombin generation plus aspirin to reduce thromboxane A2-mediated platelet activation is superior to aspirin or rivaroxaban alone for prevention of atherothrombosis in patients with coronary or peripheral artery disease, and (4) the development of inhibitors of factor XI or XII as potentially safer anticoagulants.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
    Journal:  Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. (Pubmed Central) -  Nov 21, 2019   
    Major bleeding was increased by 70%, but there was no increase in fatal or intracranial bleeding. This article (1) reviews the results of the COMPASS trial, (2) explains why dual pathway inhibition is superior to antiplatelet or anticoagulant therapy alone, (3) compares the results with rivaroxaban plus aspirin with those with other antithrombotic regimens, and (4) provides insight into how best to apply the COMPASS results into practice.
  • ||||||||||  Vitekta (elvitegravir) / Japan Tobacco, Gilead, Eliquis (apixaban) / BMS
    Clinical, Journal:  Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixaban. (Pubmed Central) -  Nov 21, 2019   
    To date, only rivaroxaban and dabigatran have reported cases of use with ritonavir-boosted ART...We report the successful use of reduced-dose apixaban to treat and prevent thromboembolic complications in six persons living with human immunodeficiency virus (HIV) on ritonavir- or cobicistat-boosted ART. This case series and available literature support the use of apixaban or dabigatran, depending on the boosted ART regimen.
  • ||||||||||  Trial completion, Trial completion date, HEOR, Real-world evidence, Real-world:  Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea (clinicaltrials.gov) -  Nov 20, 2019   
    P=N/A,  N=1, Completed, 
    AgPRP fully includes platelet ability to support TG and reveal distinct TG phases in the presence of direct FXa inhibitors highlighting its potential use in an anticoagulated setting. Recruiting --> Completed | Trial completion date: Nov 2019 --> Dec 2018
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. (Pubmed Central) -  Nov 19, 2019   
    In a retrospective analysis of medical claims data from adults treated with DOACs and hospitalized for GIB, we found that older patients who require blood and intensive care were less likely to restart treatment with DOACs after GIB. Resuming DOAC therapy was not associated with thromboembolism within 90 days or recurrence of GIB; a history of venous thromboembolism and thienopyridine use were associated with risk of subsequent thromboembolism and GIB respectively.
  • ||||||||||  Journal:  Drugs for atrial fibrillation. (Pubmed Central) -  Nov 18, 2019   
    The combination of SJW with rivaroxaban should be avoided. No abstract available
  • ||||||||||  Xarelto (rivaroxaban) / J&J
    Trial completion, Surgery:  Utilization of TEG to Monitor Rivaroxaban Activity (clinicaltrials.gov) -  Nov 15, 2019   
    P=N/A,  N=100, Completed, 
    Recruiting --> Completed | N=150 --> 51 Active, not recruiting --> Completed
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Direct oral anticoagulants in the treatment of cerebral venous sinus thrombosis: a single institution's experience. (Pubmed Central) -  Nov 14, 2019   
    The presence of enoxaparin interferes with xabans measurement by chromogenic anti-Xa assays causing falsely elevated DOAC levels, the over-estimation being dependent on the anti-Xa assay and on the heparin concentration in the sample. DOACs could be an alternative to VKA in CVST patients.